Optimizing the Care of Patients With Progressive-Fibrosing Interstitial Lung Disease: Applying the Latest Data

1.00 CME
1.00 ABIM MOC
60 MINS
$0 FEE
SAVE
Optimizing the Care of Patients With Progressive-Fibrosing Interstitial Lung Disease: Applying the Latest Data

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.


Support Statement

This activity is supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc.


Activity Description

Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (e.g., asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss challenging cases on the latest approaches to diagnosing and treating patients with PF-ILD.


Target Audience

The intended audience for this activity is pulmonologists, internists, rheumatologists and other health care professionals involved in the management of patients with progressive fibrosing interstitial lung disease (PF-ILD).


Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Implement treatment strategies for patients with PF-ILD based on the latest clinical evidence.
  • Evaluate effective multidisciplinary strategies to improve the comprehensive management of patients with PF-ILD.

Activity Chair

Steven D. Nathan, MD
Medical Director, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA


Faculty

Lisa H. Lancaster, MD
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Nina M. Patel MD
Adjunct Associate Professor of Medicine
Columbia University
New York, NY


Reviewers

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP 
Ronald A. Codario, Jr., MD


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, October 23, 2020 to October 22, 2021.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Lisa H. Lancaster, MD
Salary (Spouse): Medtronic
Consulting Fee: Bellerophon, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Genentech, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Celgene, Galapagos, Novartis, Veracyte

Steven D. Nathan, MD
Consulting Fee: Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech

Nina M. Patel MD
Advisory Board: Boehringer Ingelheim

Reviewers report the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose. 

Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non—FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com